


Atomic bomb prompts research into transplantation as a treatment for radiation marrow injury

**Dr. Georges Mathé** performs the first successful allogeneic bone marrow transplant (BMT) in a patient with leukemia, using cells from multiple related donors

**Dr. Mortimer M. Bortin** and colleagues establish the International Bone Marrow Transplant Registry (IBMTR), collecting outcomes data on transplant patients; Dr. Bortin serves as first Scientific Director (1972-1991)

Laura Graves becomes the first Fred Hutch patient to receive marrow from an unrelated marrow donor to treat her leukemia

**Dr. Robert Peter Gale** serves as the first IBMTR Chair (serving 1980-1997)



1940s

1957

1965

1968

1972

1973

1979

1980

1980

**Dr. E. Donnall Thomas** reports the first attempts at allografting resulting in transient engraftment in the *New England Journal of Medicine*; Dr. Thomas would later be awarded the Nobel Prize for his work advancing clinical transplantation

**Dr. Robert Good** of the University of Minnesota performs the first successful human leukocyte antigen (HLA)-matched sibling (non-twin) transplant for an immunological deficiency disease – clinical transplantation takes off, primarily for non-malignant disorders

First successful unrelated donor transplant performed at Memorial Sloan Kettering Cancer Center

**Dr. Al Rimm** becomes first Statistical Director (serving 1980-1993)



**CIBMTR**  
CENTER FOR INTERNATIONAL BLOOD & MARROW TRANSPLANT RESEARCH

CONTINUED  
ON NEXT SLIDE  
1980-1988

Information begins to move from paper to computers

IBMTR members visit Park City, Utah, to attend the UCLA Symposia for the first time – marking the beginning of the “annual meetings”

Dr. Mary Horowitz joins the IBMTR

The biorepository is established

US Organ Transplant Amendments Act mandates collecting outcome data for both donors and recipients (Recipient Registry is established)



1980

1981

1981

1985

1985

1986

1986

1987

1988

Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia

IBMTR receives first major National Institutes of Health (NIH) grant funding

Dr. Bob Graves, Adm. Elmo Zumwalt, and colleagues establish the National Marrow Donor Program (NMDP) with funds appropriated by the US government

NMDP facilitates its first unrelated transplant

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase

Autologous Blood and Marrow Transplant Registry of North America (ABMTR) established at the Medical College of Wisconsin; **Dr. James Armitage** subsequently became its first Advisory Committee Chair (serving 1994-1998)

T-cell depletion of HLA-identical transplants in leukemia

Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission

Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor



Graft-versus-leukemia reactions after bone marrow transplantation

**Dr. Mary Horowitz** begins her 30-year tenure as Chief Scientific Director of the IBMTR/CIBMTR

Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program

The IBMTR and ABMTR align their activities under the Medical College of Wisconsin (MCW) Statistical Center


The IBMTR/ABMTR, in conjunction with the American Society for Blood and Marrow Transplantation (ASBMT – now known as ASTCT, American Society for Transplantation and Cellular Therapy) holds the first BMT Tandem Meetings in Keystone, Colorado

**Dr. John Goldman** begins term as IBMTR Chair (serving 1998-2001)

Long-term survival and late deaths after allogeneic bone marrow transplantation

**Dr. Alexandra Filipovich** serves as IBMTR Chair (serving 2001-2002)

**Dr. Olle Ringdén** elected as IBMTR Chair, serving in this role prior to serving on the CIBMTR Transitional Advisory Committee (serving 2003-2006)



Solid cancers after bone marrow transplantation

**Dr. Armand Keating** begins term as ABMTR Chair (serving 1998-2001)

To conduct large, multi-institutional clinical trials, the IBMTR/ABMTR, NMDP, and Emmes become the Data Coordinating Center and help establish the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), which receives a grant

**Dr. Julie Vose** serves as ABMTR Chair (serving 2001-2002)

**Dr. Richard Champlin** elected as ABMTR Chair, serving in this role prior to serving on the CIBMTR Transitional Advisory Committee (serving 2003-2006)

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia

**Dr. Claudio Anasetti and Naynesh Kamani** begin terms as CIBMTR Transitional Advisory Committee Chairs (previously serving on NMDP committees, serving 2005-2006)

**Dr. Sergio Giralt** begins term as CIBMTR Advisory Committee Chair (serving 2006-2008)

Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls



The IBMTR/ABMTR at MCW and the NMDP enter a research affiliation to form the CIBMTR, integrating the research activities of the organizations – **Dr. Jeff Chell, Dennis Confer, Dan Weisdorf, and Mary Horowitz** play key roles in integrating the two research organizations

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome

Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation

The CIBMTR is awarded the contract (**PI: Dr. J. Douglas Rizzo**) for the Stem Cell Therapeutic Outcomes Database (SCTOD), part of the C.W. Bill Young (pictured above) Cell Transplantation Program

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

**Dr. Stella Davies** begins term as CIBMTR Advisory Committee Chair (serving 2008-2011)

Adverse events among 2408 unrelated donors of peripheral blood stem cells: Results of a prospective trial from the National Marrow Donor Program

**Dr. Thomas Shea** begins term as CIBMTR Advisory Committee Chair (serving 2011-2014)

Peripheral-blood stem cells versus bone marrow from unrelated donors



Electronic data reporting begins

2008 BMT Tandem Meetings reach record attendance of 2,500 registrants, with >500 proposals submitted

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia

**Dr. Paul Martin** begins term as CIBMTR Advisory Committee Chair (serving 2014-2017)

The CIBMTR starts Cellular Therapy Task Force to plan for collection of data on non-BMT cell therapies

**Dr. Robert Soiffer** begins term as CIBMTR Advisory Committee Chair (serving 2017-2020)

Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

NHLBI awards the CIBMTR a grant (**PIs: Mary Eapen and Mary Horowitz**) to work with the Cure Sickle Cell Initiative to build a research data ecosystem designed to support investigator-initiated research and clinical trials of curative therapies for sickle cell disease



Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

Receiving initial funding from the National Cancer Institute (NCI), the CIBMTR launches the Cellular Therapy Registry; this grant helped establish the Cellular Immunotherapy Data Resource (CIDR), (**PI: Marcelo Pasquini**) to accelerate research in cellular therapy for cancer

Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation

The Cure Sickle Cell Initiative is launched by the National Heart, Lung, and Blood Institute (NHLBI), to build a community of patients, advocates, researchers, and scientists to accelerate promising therapies to cure sickle cell disease

Comparison of patient age groups in transplantation for myelodysplastic syndrome: The Medicare coverage with evidence development study

The CIBMTR launches gene therapy data collection initiative with the formation of an internal Gene Therapy Working Group

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia

**Dr. Jeffery Auletta and Bronwen Shaw** named co-Chief Scientific Directors of the CIBMTR



2020



2020



2020



2020




2019



2020



2020



2020



2021

**Dr. John Wingard** begins term as CIBMTR Advisory Committee Chair (current chair, serving 2020-2023)

The CIBMTR launches the Data Transformation Initiative, contracting with a global health technology company to design, develop, and test a prototype for collecting and moving data using automation, from centers to the CIBMTR

Pandemic hits and CIBMTR responds quickly, setting up data collection on infections in transplant and cell therapy patients and addressing issues important to caring for patients in a new and challenging environment

Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis



The BMT CTN (DCC PIs: **Mary Horowitz, Steve Devine, Adam Mendizabal**) celebrates its 20th anniversary; achievements include launching >50 trials and publishing >120 peer-reviewed papers

National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide

CIBMTR, with ASTCT, hosts its 2021 meeting virtually, with >4,600 registrants

The CIBMTR celebrates the organization's 50th anniversary



Building a fit for purpose clinical trials infrastructure to accelerate the assessment of novel hematopoietic cell transplantation strategies and cellular immunotherapies

Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study



Thank you for celebrating 50 years of the CIBMTR, we look forward to the next 50 years!